Why FDA Approval of Agilent Technologies’ Assay is Important to Cervical Cancer Patients
This content is for members
Bristol-Myers Squibb (BMY)
The FDA Approves Keytruda for Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
– Keytruda becomes the first anti-PD-1 therapy to be approved for PMBCL – This is the 2nd indication for Keytruda for a hematologic malignancy. …
About Nektar’s Product NKTR- 214 at ASCO
This content is for members
A Gratifying Exelixis’ Quarterly Results
It is obvious that Exelixis’ (EXEL) first quarter results do not justify the selling of EXEL during the whole quarter, but rather condemn it. It is an …
Real Breakthroughs
This content is for members
Let’s Go Shopping
In today’s news, Incyte’s (INCY) immuno-oncology IDO1 inhibitor product Epacadostat in combination with Merck’s immuno-oncology product Keytruda® did …
Nektar Therapeutics: The Best Example of the “Sell Good News” Reckless Habit
Bristol-Myers Squibb (BMY) and Nektar Therapeutics (NKTR) Announce Global Development & Commercialization Collaboration for Nektar’s Product NKTR-214 The …
Merck’s Good News. Checkpoint Inhibitors’ Revenues
This content is for members
Last Week’s Promising News
This content is for members
Exelixis’ Exceptional Financial Results and Corporate Achievements
This content is for members
Tracing Large Pharmaceutical Companies’ Choices
This content is for members
New Breakthrough Immuno-Oncology Products
This content is for members
Prohost Letter #413
This content is for members
Some Small Outperforming Biotech Firms
This content is for members